Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers

BackgroundTreatment options for patients with metastatic uterine leiomyosarcoma are limited. Over the last few years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma.Patients and methodsA retrospective analysis was carried out on patients with uterine leiomyosarcoma treated with trabectedin at two reference sarcoma centers between 2000 and 2010. Radiological response, progression-free and overall survival, as well as serious and unexpected adverse events, were assessed.ResultsSixty-six patients with metastatic uterine leiomyosarcoma were identified. The median number of previous chemotherapy regimens was 3 (range 1–5). Eleven patients (16%) achieved a partial response and 23 (35%) had a stable disease. The progression-free survival of the entire cohort was 3.3 months (CI 95% 2–5), and the progression-free rate at 3 and 6 months was 53% and 33%, respectively.ConclusionsTrabectedin is a therapeutic option in the palliative approach to the metastatic uterine leiomyosarcoma patient.

► Uterine leiomyosarcoma is a disease with limited treatment options.
► We retrospectively reviewed 66 advanced uterine leiomyosarcomas treated with Trabectedin and we saw 16% PR and 35% SD.
► Trabectedin is an option in the treatment of metastatic uterine leiomyosarcoma.